About Seahorse Bioscience
Seahorse Bioscience is a company based in Boston (United States) founded in 2000 was acquired by Agilent in September 2015. Seahorse Bioscience has raised $34.85 million across 5 funding rounds from investors including FLIR, Agilent and Flagship Pioneering. Seahorse Bioscience operates in a competitive market with competitors including Alamar Biosciences, Glympse Bio, Harmonic Discovery, Cellarcus Biosciences and Luceome Biotechnologies, among others.
- Headquarter Boston, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Seahorse Bioscience
Unlock access to complete
Funding Insights of Seahorse Bioscience
Seahorse Bioscience has successfully raised a total of $34.85M across 5 strategic funding rounds. The most recent funding activity was a Series E round of $11.35 million completed in March 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Seahorse Bioscience
Seahorse Bioscience has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include FLIR, Agilent and Flagship Pioneering.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech & offline focused VC firm investing in early & growth stage startups in the US
|
Locked | Locked | Locked | |
|
Private equity investments in life sciences businesses are managed.
|
Locked | Locked | Locked | |
|
Early stage VC firm investing in the US and Korea
|
Locked | Locked | Locked |
Investor details for Seahorse Bioscience
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Seahorse Bioscience
Investment portfolio details for Seahorse Bioscience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Seahorse Bioscience
Detailed financials for Seahorse Bioscience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Seahorse Bioscience Comparisons
Peer comparison for Seahorse Bioscience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Seahorse Bioscience
Seahorse Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alamar Biosciences, Glympse Bio, Harmonic Discovery, Cellarcus Biosciences and Luceome Biotechnologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Ultra-high sensitivity protein analysis solutions are provided across multiplex levels.
|
|
| Locked | Locked | Locked |
Multiple human diseases are monitored noninvasively through urine-based analysis.
|
|
| Locked | Locked | Locked |
Developer of kinase inhibitor drugs for oncology
|
|
| Locked | Locked | Locked |
Provider of extracellular vesicle analysis assay
|
|
| Locked | Locked | Locked |
Assay technology is developed for identifying drugs against kinases.
|
Detailed competitors of Seahorse Bioscience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Seahorse Bioscience
Complete news archive for Seahorse Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Seahorse Bioscience
Seahorse Bioscience was founded in 2000 and raised its 1st funding round 2 years after it was founded.
Seahorse Bioscience is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Seahorse Bioscience is a funded company, having raised a total of $34.85M across 5 funding rounds to date.
Seahorse Bioscience has developed an instrument system, called the Seahorse XFp Analyzer to assay the metabolic status of cells by measuring the Oxygen Consumption Rate (OCR) - a measure of the cellular respiration, and extracellular acidification rate (ECAR) - a measure of the rate of glycolysis, at regular intervals (5-8 minutes) using solid state sensor probes. The OCRECAR measurements can be used as metabolic phenotypes in various cellular assays and diagnostic tests. The company has developed both the instrumentation, as well as reagents and consumables to be used for the assays on the Seahorse XFp Analyzer. The company was acquired by Agilent Technologies in September 2015, which currently manufactures and sells the instrument system.
Seahorse Bioscience's top competitors include Alamar Biosciences, Glympse Bio and Harmonic Discovery.
Seahorse Bioscience has 10 investors. Key investors include FLIR, Agilent, Flagship Pioneering, Life Sciences Partners, and Commonwealth Capital Ventures.